Alzamend Neuro, Inc. — Form 10-K summary
Reporting period: Fiscal year ended April 30, 2023; filed July 27, 2023. Although the request metadata refers to 2022 Q4, this filing reports full fiscal years 2023 and 2022, not a standalone quarter.
Business context
Alzamend is a clinical-stage biopharmaceutical company with no product revenue. It is developing AL001, a lithium-based ionic cocrystal licensed for Alzheimer’s disease and other indications, and ALZN002, an investigational cell-based immunotherapy for Alzheimer’s. Both programs require further clinical development, regulatory approval, and substantial financing before they could generate revenue.
Key financial metrics
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $7.45 million | $5.20 million |
| General and administrative expense | $7.42 million | $7.12 million |
| Total operating expenses | $14.87 million | $12.32 million |
| Net loss | $14.88 million | $12.36 million |
| Basic and diluted loss per share | $0.15 | $0.14 |
| Cash used in operating activities | $8.92 million | $6.61 million |
| Cash and cash equivalents at year-end | $5.14 million | $14.06 million |
| Total assets | $5.92 million | $14.52 million |
| Total liabilities | $2.87 million | $1.16 million |
Gross margin and operating margin are not meaningful for this pre-revenue company, and the filing does not provide a clear margin measure. The company reported $3.05 million of stockholders’ equity. It also reported a $14.88 million related-party note receivable, recorded as a reduction to equity; this is not presented as company debt. The note is due December 31, 2023. No conventional debt balance is clearly reported in the balance sheet.
Current assets were $5.84 million against current liabilities of $2.87 million. Management stated that available cash was expected to fund operations for approximately six months without additional funding and was insufficient to fund planned operations for one year after issuance of the financial statements.
Changes versus prior year
- Operating expenses rose 21%, chiefly reflecting higher R&D costs; clinical-trial fees increased to $2.47 million from $0.20 million as AL001 studies advanced.
- Net loss increased about 20%, while cash used in operations rose about 35%.
- Cash fell by $8.92 million during FY2023. Financing activities contributed only $200, compared with $18.85 million in FY2022, which included IPO proceeds and related-party equity financing.
- Shares outstanding increased to 96.94 million at April 30, 2023 from 95.48 million a year earlier. The company also issued 933,334 shares to related party AULT for marketing and brand-development services.
Outlook, risks, and unusual items
- Funding and going concern: The auditor expressed substantial doubt about the company’s ability to continue as a going concern. Management expects continuing losses and plans to seek equity, private financing, debt, warrant proceeds, or other funding. Failure to raise capital could delay, reduce, or end development programs.
- Development outlook: The Phase IIA multiple-ascending-dose study of AL001 was completed in March 2023; the company announced positive topline information in June 2023, after fiscal year-end. Management reported identifying a maximum tolerated dose equivalent to 240 mg lithium carbonate three times daily. This is safety/dose information, not proof of efficacy. The company planned two Alzheimer’s safety-and-efficacy studies and intended to submit IND applications for AL001 in bipolar disorder, major depressive disorder, and PTSD by the end of 2023, subject to financing. ALZN002’s Phase I/IIA trial began in April 2023; management expected a larger Phase IIB trial after initial-trial data.
- Licensing obligations: The University of South Florida licensor may terminate licenses for missed milestones. Disclosed future milestones include a $50,000 ALZN002 payment tied to first patient dosing, scheduled for September 2023, and larger payments tied to later trial and approval milestones. License royalties are 4.5% on AL001 Alzheimer’s net sales, 3% on AL001 sales in additional fields, and 4% on ALZN002 net sales.
- Related parties: A $14.88 million related-party note receivable from Ault Life Sciences Fund remained outstanding and due December 31, 2023. The company also disclosed overlapping leadership and ownership ties with AULT and related entities, plus the $1.4 million AULT marketing agreement settled in shares.
- Regulatory and legal: The company disclosed a 2019 SEC subpoena concerning an investigation of DPW Holdings (now AULT); its scope, outcome, and potential impact were unknown, and no loss provision had been established. The filing also said the company was not meeting Nasdaq’s minimum bid-price requirement and had until July 31, 2023 to regain compliance.
- Controls and audit: Management concluded disclosure controls and internal control over financial reporting were ineffective at April 30, 2023, citing limited accounting staffing and weaknesses in financial-system access and change-management controls. Remediation was underway. The auditor gave an unqualified opinion on the financial statements, but did not express an opinion on control effectiveness.
- Other: No pending legal or arbitration proceedings were reported. The company had no employees beyond four full-time and three part-time staff, relied on outside manufacturers, and reported no dividends paid or planned in the foreseeable future.
Important facts for investors to verify
- Whether subsequent financing was obtained, the amount and terms, and the resulting dilution and cash runway.
- Whether the related-party $14.88 million note was repaid by its December 31, 2023 maturity, and whether the potential additional $10 million Ault Lending investment right was exercised or expired.
- Full AL001 and ALZN002 trial data, including safety, efficacy, enrollment, timing, and any FDA feedback; distinguish topline dose findings from demonstrated clinical benefit.
- Whether the company regained Nasdaq minimum-bid compliance by the stated deadline and remained listed.
- Progress and independent testing of internal-control remediation, and any developments in the SEC inquiry or related-party arrangements.
- Current status of license milestones, patent protection, and the company’s ability to meet contractual payments without disrupting development.